|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | Tel-Aviv Sourasky Medical Center |
|---|---|
| Information provided by: | Tel-Aviv Sourasky Medical Center |
| ClinicalTrials.gov Identifier: | NCT00267813 |
Purpose
Craving and withdrawal from smoking cigarettes are major factors for relapse. We investigated craving for cigarettes in smokers undergoing pharmacological treatment with Bupropion (Zyban). We compare cue-induced reactivity to smoking videos in smokers who were successfully treated with Bupropion to smokers who are still smoking. We measured the brain's metabolic activity in response to smoking and neutral cues in Positron Emission Tomography using FDG.
| Condition | Intervention |
|---|---|
|
Nicotine Dependence |
Drug: Bupropion (Zyban) |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacodynamics Study |
| Official Title: | The Effects of Craving and Abstinence From Cigarettes on Brain Metabolism in Smokers. |
| Enrollment: | 24 |
| Study Start Date: | July 2004 |
| Study Completion Date: | October 2007 |
| Primary Completion Date: | October 2007 (Final data collection date for primary outcome measure) |
Craving and withdrawal from smoking cigarettes are major factors for relapse. We investigated craving for cigarettes in smokers undergoing pharmacological treatment with Bupropion (Zyban)for 2 months. We compare cue-induced reactivity to smoking videos in smokers who were successfully treated with Bupropion to smokers who are still smoking. We measured the brain's metabolic activity after exposure to videotapes showing smoking and neutral scenes in Positron Emission Tomography using FDG. There were 2 scanning sessions, one with a smoking videotape and one with a neutral video separated by a week. So far we have compared the brain's metabolic activity in 6 abstinent smokers and 6 still smokers.
Eligibility| Ages Eligible for Study: | 20 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Israel | |
| Department of Nuclear Medicine | |
| Tel Aviv, Israel, 64239 | |
| Principal Investigator: | Einat Even-Sapir, M.D, Ph.D | Tel-Aviv Sourasky Medical Center |
| Principal Investigator: | Aviv M Weinstein, Ph.D | Tel-Aviv Sourasky Medical Center |
| Study Director: | Hedva Lerman, M.D | Tel-Aviv Sourasky Medical Center |
More Information
| Responsible Party: | Sourasky Medical Center Tel Aviv ( Dr. Aviv M. Weinstein ) |
| Study ID Numbers: | TASMC-O5-EE-065-CTIL |
| Study First Received: | December 20, 2005 |
| Last Updated: | May 6, 2008 |
| ClinicalTrials.gov Identifier: | NCT00267813 History of Changes |
| Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
|
craving nicotine imaging FDG |
PET smoking Bupropion |
|
Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Tobacco Use Disorder Physiological Effects of Drugs Psychotropic Drugs Disorders of Environmental Origin Pharmacologic Actions |
Mental Disorders Therapeutic Uses Bupropion Substance-Related Disorders Dopamine Agents Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |
